Latiglutenase

DRUG3 trials

Sponsors

Immunogenics, LLC, Entero Therapeutics

Conditions

Celiac Disease

Phase 2

Latiglutenase as a Treatment for Celiac Disease

CompletedNCT03585478

Immunogenics, LLCCeliac Disease

Start: 2019-03-01End: 2021-01-22Updated: 2021-12-15

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

TerminatedNCT04243551

Entero TherapeuticsCeliac Disease

Start: 2019-11-01End: 2023-10-31Updated: 2024-08-05

Study of Latiglutenase in T1D/CD Patients

TerminatedNCT04839575

Entero TherapeuticsCeliac Disease

Start: 2021-04-06End: 2022-12-19Updated: 2024-08-05

Related Papers

Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge.

2022-08-0245 citations